-
-
-
-
-
-
-
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
-
-
-
-
-
-
-
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
-
-
-
-
-
-
-
/C O R R E C T I O N -- UCB/
-
-
-
-
-
-
-
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
-
-
-
-
-
-
-
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
-
-
-
-
-
-
-
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
-
-
-
-
-
-
-
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
-
1,188,125 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

